| 000 | 01693 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518031704.0 | ||
| 264 | 0 | _c20200320 | |
| 008 | 202003s 0 0 eng d | ||
| 022 | _a1462-0332 | ||
| 024 | 7 |
_a10.1093/rheumatology/kez091 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAdler, Sabine | |
| 245 | 0 | 0 |
_aRisk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. _h[electronic resource] |
| 260 |
_bRheumatology (Oxford, England) _c09 2019 |
||
| 300 |
_a1639-1643 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGiant Cell Arteritis _xdiagnostic imaging |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMagnetic Resonance Angiography |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 |
_aRisk Assessment _xmethods |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aWithholding Treatment |
| 700 | 1 | _aReichenbach, Stephan | |
| 700 | 1 | _aGloor, Andrea | |
| 700 | 1 | _aYerly, Daniel | |
| 700 | 1 | _aCullmann, Jennifer L | |
| 700 | 1 | _aVilliger, Peter M | |
| 773 | 0 |
_tRheumatology (Oxford, England) _gvol. 58 _gno. 9 _gp. 1639-1643 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/rheumatology/kez091 _zAvailable from publisher's website |
| 999 |
_c29520588 _d29520588 |
||